IBS Irritable Bowl Syndrome

65. Thompson DG. Clinical pharmacology. In: Functional disorders of the gut. Eds:
Philips SF, Wingate DL. Churchill Livingstone, London, 1998:pp43–51.
66. Gorard DA, Libby GW, Farthing MJG. Effect of a tricyclic antidepressant on small
intestinal motility in health and in diarrhoea-predominant irritable bowel
syndrome. Dig Dis Sci 1995;40:86–95.
67. Gorard DA, Libby GW, Farthing MJG. 5-hydroxytryptamine and human small
intestine motility: effect of inhibiting 5-hydroxytryptamine uptake. Gut 1994;
35:496–500.
68. Klein KB. Controlled treatment trials in the irritable bowel syndrome: a critique.
Gastroenterology 1988;95:232–41.
69. Gralla RJ, Navari RM, Hesketh PJ et al. Single-dose oral granisetron has
equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic
cisplatin-based chemotherapy. J Clin Oncol 1998;16:1568–73.
70. Talley NJ, Phillips SF, Haddad A et al. GR 38032F (ondansetron), a selective
5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci
1990;35:477–80.
71. Von der Ohe MR, Hanson RB, Camilleri M. Serotonergic mediation of
postprandial colonic tonic and phasic responses in humans. Gut 1994;35:
536–41.
72. Goldberg PA, Kamm MA, Setti-Carraro P, van der Sijp JR, Roth C. Modification of
visceral sensitivity and pain in irritable bowel syndrome by 5-HT3 antagonism
(ondansetron). Digestion 1996;57:478–83.
73. Camilleri M, Mayer EA, Drossman DA et al. Improvement in pain and bowel
function in female irritable bowel patients with alosetron, a 5-HT3 receptor
antagonist. Alim Pharm Ther 1999;13:1149–59.
74. Houghton LA, Jackson NA, Whorwell PJ, Cooper S. 5-HT4 antagonism in irritable
bowel syndrome (IBS): effect of SB-207266-A on rectal sensitivity and small
bowel transit [abstract]. Gut 1997;41(Suppl. 3):17.09.
75. Miner PB Jr, Nichols T Jr, Silvers DR, Joslyn A, Woods M. The efficacy and safety
of prucalopride in patients with chronic constipation. Gastroenterology 1999;
116.4:A1042
76. Schmitt C, Krumholz S, Tanghe J, Heggland J, Shi Y, Lefkowitz M. Tegaserod,
a partial 5-HT4 agonist improves abdominal discomfort/pain in irritable bowel
syndrome (IBS). Gut 1999;45(Suppl. V):A258(P0960).
77. Krumholz S, Tanghe J, Schmitt C, Heggland J, Shi Y, Rüegg PC. The 5-HT4 receptor partial agonist tegaserod improves abdominal bloating and altered
stool consistency in irritable bowel syndrome. Gut 1999;45(Suppl. V):A260
(PO965).
43